[A24-99] Pembrolizumab (urothelial cancer, first line) – Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2025
Project no.:
A24-99
Commission:
Commission awarded on 24.09.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
First-line treatment of adult patients with unresectable or metastatic urothelial carcinoma
Result of dossier assessment:
- Patients for whom cisplatin-based therapy is a suitable treatment option: hint of non-quantifiable added benefit.
- Patients for whom cisplatin-based therapy is not a suitable treatment option: hint of major added benefit.
- Patients for whom cisplatin-based and carboplatin-based therapy is not a suitable treatment option: added benefit not proven.
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-99